Panacea Biotec, RDIF agree to produce 100 million doses of Sputnik V vaccine in India per year

06 Apr 2021 Evaluate

Panacea Biotec and the Russian Direct Investment Fund (RDIF, Russia's sovereign wealth fund) have agreed to produce 100 million doses per year of Sputnik V, the world's first registered vaccine against coronavirus. Production of Sputnik V at Panacea Biotec sites will help facilitate global supply of Sputnik V to international partners of RDIF.

To date Sputnik V has been registered in 59 countries globally with total population of over 1.5 billion people. Efficacy of Sputnik V is 91.6% as confirmed by the data published in the Lancet, one of the world's oldest and most respected medical journals. The vaccine is based on a proven and well-studied platform of human adenoviral vectors and uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shot.

Panacea Biotec is a leading research based Biotechnology Company with established research, manufacturing and marketing capabilities.

Panacea Biotec Share Price

563.65 26.60 (4.95%)
29-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.80
Dr. Reddys Lab 1176.25
Cipla 1541.00
Lupin 2067.40
Zydus Lifesciences 887.95
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...